Search results for: Multi-Indication Medicines
Filter search results
The Impact of New Medicines in the NHS: 70 Years of Innovation
1 August 2018
…from new medicines. Their role should be considered in the use of medicines in the NHS over the next 70 years and for new medicines currently in the development pipeline….
OHE at ISPOR Washington DC (1): HTA, Evidence and Pricing
9 June 2016
…this issue panel; please see his slides below. Adrian presented a European perspective on multi-indication drug including options from an OHE supported stakeholder forum. “Multi-indication Pricing: Do we want it?…
OHE at HTAi Rome
12 July 2017
…Value Assessment of Multi-Indication Products: Practical Solutions and Steps. Adrian introduced the topic, noting that increasing numbers of new drugs have several indications. The challenge is to agree an efficient…
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
1 July 2019
…medicines based on the example of Second-Generation Antipsychotics (SGA). Assessing the entire life-cycle of SGA, the study explores how much additional value has been delivered through additional approved indications for…
Valuing Orphan Medicines Using Multi-Criteria Decision Analysis
7 May 2013
…medicines are concerned. Policy makers and payers continue in seek improvements in approaches to determining the value of medicines. The move towards “value based pricing” in the UK is just…
OHE at HTAi 2017: Meet the Team
13 June 2017
…countries, however their access is restricted by reimbursement policies (especially in the UK, Italy and Spain). Panel: Value Assessment of Multi-Indication Products: Practical Solutions and Steps OHE Authors: Adrian Towse…
Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
1 December 2017
…and made mandatory for orphan and oncology medicines. We analysed routine funding in the NHS for new medicines recently authorised via the centralised procedure with a particular focus on oncology…
The Spanish Medicines Market Today
9 February 2011
…medicines whose retail price is less than €3.12. Expected savings from these cuts are €169m. In June 2010, new rebates were announced affecting only patented medicines reimbursed under the NHS….
Routine Funding in the UK NHS of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
18 December 2017
…to innovative medicines across the European Union (EU). Since then the scope of authorisation via the centralised procedure has been broadened and made mandatory for orphan and oncology medicines. We…